Non-alcoholic fatty liver disease in people with impaired glucose tolerance and type 2 diabetes mellitus: Modern approaches to therapy
https://doi.org/10.62751/2713-0177-2026-7-1-08
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by the accumulation of lipids in hepatocytes caused by metabolic disorders. This disease is widespread all over the world, and its scale is only now beginning to be assessed. Due to the epidemic of associated diseases such as obesity and type 2 diabetes mellitus (T2DM2), the issues of the pathogenesis and treatment of NAFLD are becoming increasingly relevant. The main pathophysiological mechanisms of NAFLD are insulin resistance, glucotoxicity and lipotoxicity, and impaired insulin metabolism, which explains the relationship between NAFLD and T2DM. At the moment, new approaches to the drug correction of NAFLD are being actively sought. Sodium glucose cotransporter type 2 (SGLT2) inhibitors are a modern class of drugs that are used to treat T2DM2 and a wide range of related complications, such as chronic kidney disease or heart failure. The mechanism of action of SGLT2 inhibitors is based on a decrease in glucose reabsorption by the kidneys and an increase in glucose excretion in the urine by suppressing two glucose transporters in the kidneys: sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2). The use of this group of drugs has already gone beyond endocrine pathology, due to their proven cardio- and nephroprotective properties. Due to the improvement of the metabolic profile when using them, the question of using SGLT2 inhibitors as an independent therapy for NAFLD is being actively discussed.
Keywords
non-alcoholic fatty liver disease,
type 2 diabetes mellitus,
type 2 sodium-glucose cotransporter inhibitors,
insulin resistance
Supporting agencies: None
About the Authors
K. M. Sarycheva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Kseniia M. Sarycheva, postgraduate student
Department of hospital therapy named after G.I. Storozhakov
117593; 1А, Lithuanian Boulevard; Moscow
I. G. Nikitin
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Igor G. Nikitin, Dr. Sci. (Med.), professor
Moscow
References
1. Raikhelson KL, Maevskaya MV, Zharkova MS, Grechishnikova VR, Okovityy SV, Deeva TA, et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44 (In Russ.) doi: 10.22416/1382-4376-2024-961
2. Cusi K. Nonalcoholic fatty liver disease in diabetes: A call to action. Diabetes Spectr. 2024;37(1):5–7. doi: 10.2337/dsi23-0015
3. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–44. doi: 10.1016/j.jhep.2018.10.033
4. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312
5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. doi: 10.1097/HEP.0000000000000520
6. Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, et al. Non-alcoholic fatty liver disease and cardiovascular comorbidities: Pathophysiological links, diagnosis, and therapeutic management. Diagnostics (Basel). 2021;11(4):689. doi: 10.3390/diagnostics11040689
7. Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: Time for action. Diabetes Spectr. 2024;37(1):9–19. doi: 10.2337/dsi23-0010
8. Cusi K. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver Int. 2020;40 Suppl 1:82–88. doi: 10.1111/liv.14350
9. Ivashkin VT, Zharkova MS, Korochanskaya NV, Khlynov IB, Uspensky YuP. Phenotypes of non-alcoholic fatty liver disease in different regions of the Russian Federation, diagnostic and therapeutic approach in clinical practice. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):7–18 (In Russ.) doi: 10.22416/1382-4376-2023-33-2-7-18
10. Kosobyan EP, Smirnova OM. Current concepts of the pathogenesis of non-alcoholic fatty liver disease. Sakharnyy diabet = Diabetes Mellitus. 2010;13(1):55–64 (In Russ.) doi: 10.14341/2072-0351-6018
11. Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52(1):25–37. doi: 10.1016/j.arcmed.2020.11.010
12. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–108. doi: 10.1016/j.metabol.2016.01.001
13. Margariti A, Kontogianni MD, Tileli N, Georgoulis M, Deutsch M, Zafeiropoulou R, et al. Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(8):907–13. doi: 10.1097/MEG.0000000000000381
14. Parry SA, Hodson L. Managing NAFLD in type 2 diabetes: The effect of life-style interventions, a narrative review. Adv Ther. 2020;37(4):1381–406. doi: 10.1007/s12325-020-01281-6
15. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22(5):756–61. doi: 10.2337/diacare.22.5.756
16. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus : A systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–48. doi: 10.1002/ijc.26165
17. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361–71. doi: 10.1002/hep.29724
18. Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol. 2016;65(4):791–97. doi: 10.1016/j.jhep.2016.05.026
19. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD) : A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. doi: 10.1186/s12902-022-00980-1
20. Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease : A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(6):1470–78. doi: 10.1111/jgh.15363
21. Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023;13:1087260. doi: 10.3389/fendo.2022.1087260
22. Shi R, Chai K, Wang H, Zhou J, Yang S, Li J, et al. Clinical assessment of common medications for nonalcoholic fatty liver disease : A systematic review and Bayesian network meta‐analysis. J Evid Based Med. 2025;18(1):e70002. doi: 10.1111/jebm.70002
23. Mayevskaya MV, Nadinskaia MYu, Lunkov VD, Pirogova IYu, Chesnokov EV, Kodzoeva KhB, Ivashkin VT. An Effect of Ursodeoxycholic Acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease: Results of the USPEH Study. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22–29 (In Russ.) doi: 10.22416/1382-4376-2019-29-6-22-29
24. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–30. doi: 10.2174/138161212799504803
25. Lee HA, Kim HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci. 2023;24(11):9324. doi: 10.3390/ijms24119324
26. Sabirov IS, Murkamilov IT, Fomin VV, Murkamilova ZhA, Sabirova AI. SGLT-2 inhibitors in chronic kidney disease: State of the art. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2022;31(3):53–58 (In Russ.) doi: 10.32756/0869-5490-2022-3-53-58.
27. Demidova TYu, Teplova AS, Stepanova EV, Amirian DS. From metabolism to pathology: The role of sodium-glucose cotransporter-1 in the pathogenesis of type 2 diabetes mellitus. FOCUS Endokrinologia = FOCUS Endocrinology. 2024;5(3):55–63 (In Russ.) doi: 10.62751/2713-0177-2024-5-3-07
28. Plakhotnyaya VM, Martynova EYu, Poteshkin YuE. Sodium-glucose cotransporter 1: A role in the pathogenesis of type 2 diabetes mellitus and other diseases and a potential therapeutic target. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2022;18(2):42–54 (In Russ.) doi: 10.33978/2307-3586-2022-18-2-42-54
29. Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci. 2023;24(20):15473. doi: 10.3390/ijms242015473
Review
For citations:
Sarycheva K.M., Nikitin I.G. Non-alcoholic fatty liver disease in people with impaired glucose tolerance and type 2 diabetes mellitus: Modern approaches to therapy. FOCUS. Endocrinology. 2026;7(1):58-65. (In Russ.) https://doi.org/10.62751/2713-0177-2026-7-1-08
Views:
91
JATS XML
Email this article 